Evaluate whether management allocates capital wisely or recklessly. Capital allocation track record scoring and investment history to identify leadership teams that consistently create shareholder value. Assess capital allocation with comprehensive analysis.
Pasithea Therapeutics (KTTA) has been trading in a narrow range recently, with shares hovering near the $0.78 level—only a modest gain of 0.28% on the day. The stock continues to find support around $0.74, a zone that has held steady in recent sessions, while resistance near $0.82 has capped upside
Pasithea Therapeutics (KTTA) Stalls at $0.78 — Breakout or Breakdown? 2026-05-18 - Median Line
KTTA - Stock Analysis
3850 Comments
1877 Likes
1
Nicolau
Senior Contributor
2 hours ago
I read this like it was breaking news.
👍 110
Reply
2
Seairah
Consistent User
5 hours ago
Comprehensive US stock backtesting and historical performance analysis to validate investment strategies before committing capital. We provide extensive historical data that allows you to test any trading idea before risking real money.
👍 279
Reply
3
Hersey
Registered User
1 day ago
I need to find others thinking the same.
👍 56
Reply
4
Lacynthia
Loyal User
1 day ago
I’m pretending I understood all of that.
👍 228
Reply
5
Charlirae
Loyal User
2 days ago
Anyone else just realized this?
👍 40
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.